Autopsy report · NCT00913913

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

“low accrual not allowing site to meeting statistical endpoints”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 3 years 11 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 2 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Dartmouth-Hitchcock Medical Center

Sponsor type

University, hospital or other

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DC vaccine; Bevacizumab; IL-2; IFN

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• A Phase I/Expansion Study of Dasatinib
  “Low accrual, unable to meet endpoint in timely manner” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.